Department of Neurology, Yonsei University College of Medicine, Seoul, 03722, Korea.
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Korea.
Sci Rep. 2018 Apr 3;8(1):5557. doi: 10.1038/s41598-018-23676-w.
We aimed to compare the longitudinal outcome of amnestic mild cognitive impairment (aMCI) patients with significant Pittsburgh Compound B uptake [PiB(+) aMCI] and those without [PiB(-) aMCI]. Cerebral β-amyloid was measured in 47 patients with aMCI using PiB-positron emission tomography (PET) (31 PiB(+) aMCI and 16 PiB(-) aMCI). Clinical (N = 47) and neuropsychological follow-up (N = 37), and follow-up with brain magnetic resonance imaging (N = 38) and PiB-PET (N = 30) were performed for three years. PiB(+) aMCI had a higher risk of progression to dementia (hazard ratio = 3.74, 95% CI = 1.21-11.58) and faster rate of cortical thinning in the bilateral precuneus and right medial and lateral temporal cortices compared to PiB(-) aMCI. Among six PiB(-) aMCI patients who had regional PiB uptake ratio >1.5 in the posterior cingulate cortex (PCC), three (50.0%) progressed to dementia, and two of them had global PiB uptake ratio >1.5 at the follow-up PiB-PET. Our findings suggest that amyloid imaging is important for predicting the prognosis of aMCI patients, and that it is necessary to pay more attention to PiB(-) aMCI with increased regional PiB uptake in the PCC.
我们旨在比较有明显匹兹堡化合物 B 摄取的遗忘型轻度认知障碍(aMCI)患者(PiB(+) aMCI)和无明显匹兹堡化合物 B 摄取的 aMCI 患者(PiB(-) aMCI)的纵向结局。使用 PiB-正电子发射断层扫描(PET)对 47 名 aMCI 患者进行脑β-淀粉样蛋白测量(31 名 PiB(+) aMCI 和 16 名 PiB(-) aMCI)。对 47 名患者进行了为期三年的临床(N=47)和神经心理学随访(N=37),以及脑磁共振成像(N=38)和 PiB-PET 随访(N=30)。与 PiB(-) aMCI 相比,PiB(+) aMCI 向痴呆进展的风险更高(危险比=3.74,95%可信区间=1.21-11.58),双侧楔前叶和右侧内侧和外侧颞叶皮质的皮质变薄速度更快。在 6 名 PCC 局部 PiB 摄取比值大于 1.5 的 PiB(-) aMCI 患者中,有 3 名(50.0%)进展为痴呆,其中 2 名在随访的 PiB-PET 中出现全局 PiB 摄取比值大于 1.5。我们的研究结果表明,淀粉样蛋白成像对于预测 aMCI 患者的预后很重要,因此有必要更加关注 PCC 局部 PiB 摄取增加的 PiB(-) aMCI。